Discovery - University of Dundee - Online Publications

Library & Learning Centre

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes : an analysis from the CARDS trial

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Helen M. Colhoun (Lead / Corresponding author)
  • D. John Betteridge
  • Paul Durrington
  • Graham Hitman
  • Andrew Neil
  • Shona Livingstone
  • Valentine Charlton-Menys
  • Weihang Bao
  • David A. DeMicco
  • Gregory M. Preston
  • Harshal Deshmukh
  • Kathryn Tan
  • John H. Fuller

Research units

    Info

    Original languageEnglish
    Pages2379-2385
    Number of pages7
    JournalDiabetes
    Journal publication dateSep 2011
    Journal number9
    Volume60
    DOIs
    StatePublished

    Abstract

    OBJECTIVE-Circulating levels of soluble receptor for advanced glycation end products (sRAGE) likely comprise both a secreted isoforrn (esRAGE) and wild-type RAGE cleaved from the cell membrane. Both sRAGE and esRAGE have been proposed as biomarkers of cardiovascular disease (CVD), but prospective data are limited. We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS).

    RESEARCH DESIGN AND METHODS-We used a nested case-control design sampling all incident cases of CVD with available plasma and randomly selecting three control subjects, who were free of CVD throughout follow-up, per case. Analysis was by Cox regression with adjustment for treatment allocation and relevant covariates.

    RESULTS-sRAGE and esRAGE were strongly correlated (rho = 0.88) and were both higher in those with lower BMI (P < 0.001), higher adiponectin (P < 0.001), lower estimated glomerular filtration rate (P = 0.009), and white ethnicity (P < 0.001). Both sRAGE and esRAGE were associated with incident CHD events, independently of treatment allocation and the above factors; hazard ratio (HR) = 1.74 (95% CI 1.25-2.41; P = 0.002) for a doubling of the sRAGE level; HR = 1.45 (1.11-1.89; P = 0.006) for a doubling of the esRAGE level. There was no significant association with stroke; HR for sRAGE = 0.66 (0.38-1.14). Atorvastatin, 10 mg daily, did not alter sRAGE.

    CONCLUSIONS-Higher levels of sRAGE and esRAGE are associated with incident CHD but not stroke in type 2 diabetes. Diabetes 60:2379-2385, 2011

    Documents

    Library & Learning Centre

    Contact | Accessibility | Policy